ArticleThe Eurasian journal of medicine2025
Investigation of Hepatitis B Virus (HBsAg, Anti-HBs) and Anti-Hepatitis C Virus Serology in Erzurum Region: 2015-2023.
Article in The Eurasian journal of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are among the problems affecting public health worldwide. In this study, we aimed to retrospectively examine the results of patients whose hepatitis B (hepatitis B surface antigen (HBsAg), anti-HBs (Hepatitis B surface antibody) and hepatitis C serology were analyzed by family physicians in the provincial center of Erzurum and to investigate the change in seroprevalence by gender, age groups, and years. Methods: The serology results of individuals whose HBV and anti-HCV serology were analyzed by family physicians in Erzurum between 2015-2023 were evaluated retrospectively. Hepatitis B virus and anti-HCV analyses of the patients were performed in the Public Health Microbiology Laboratory using the chemilu minescence enzyme immunoassay method in accordance with the study procedure of the producing company. These records of the patients were obtained from the laboratory automation system with permission obtained from the Health Directorate. Results: Our study's population consisted of 150 862 people. The study determined that HBsAg, anti-HBs, and anti-HCV seropositivity rates were 1.7%, 58.0%, and 0.02%, respectively. The difference between HBsAg and anti-HBs seropositivity results was statistically significant between individuals born before 1998 and those born after 1998. Conclusion: In our study, it is significant that the HBsAg positivity rate tends to decrease, and anti-HBs sero- positivity has been observed at higher rates in recent years. The rate of anti-HCV seropositivity was found to be lower compared to other studies conducted in our region.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.